Hellen Oduor1, Caterina P Minniti2, Alessandra Brofferio3, Ahmed M Gharib4, Khaled Z Abd-Elmoniem4, Matthew M Hsieh5, John F Tisdale5, Courtney D Fitzhugh1,5. 1. Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland. 2. Division of Hematology, Department of Medicine, Einstein College of Medicine, Bronx, New York. 3. Cardiovascular Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland. 4. Biomedical and Metabolic Imaging Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 5. Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
Abstract
BACKGROUND: Use of chronic blood transfusions as a treatment modality in patients with blood disorders places them at risk for iron overload. Since patients with β-thalassemia major (TM) are transfusion-dependent, most studies on iron overload and chelation have been conducted in this population. While available data suggest that compared to TM, patients with sickle cell disease (SCD) have a lower risk of extrahepatic iron overload, significant iron overload can develop. Further, previous studies have demonstrated a direct relationship between iron overload and morbidity and mortality rates in SCD. However, reports describing the outcome for patients with SCD and cardiac iron overload are rare. STUDY DESIGN AND METHODS: We performed a retrospective analysis and identified two SCD patients with cardiac iron overload. We provide detailed descriptions of both cases and their outcomes. RESULTS: Serum ferritin levels ranged between 17,000 and 19,000 μg/L. Both had liver iron concentrations in excess of 35 mg of iron per gram of dried tissue as well as evidence of cardiac iron deposition on magnetic resonance imaging. One patient died of an arrhythmia and had evidence of severe multiorgan iron overload via autopsy. On the other hand, after appropriate therapy, a second patient had improvement in cardiac function. CONCLUSION: Improper treatment of iron overload in SCD can lead to a fatal outcome. Alternatively, iron overload may potentially be prevented or reversed with judicious use of blood transfusions and early use of chelation therapy, respectively.
BACKGROUND: Use of chronic blood transfusions as a treatment modality in patients with blood disorders places them at risk for iron overload. Since patients with β-thalassemia major (TM) are transfusion-dependent, most studies on iron overload and chelation have been conducted in this population. While available data suggest that compared to TM, patients with sickle cell disease (SCD) have a lower risk of extrahepatic iron overload, significant iron overload can develop. Further, previous studies have demonstrated a direct relationship between iron overload and morbidity and mortality rates in SCD. However, reports describing the outcome for patients with SCD and cardiac iron overload are rare. STUDY DESIGN AND METHODS: We performed a retrospective analysis and identified two SCDpatients with cardiac iron overload. We provide detailed descriptions of both cases and their outcomes. RESULTS: Serum ferritin levels ranged between 17,000 and 19,000 μg/L. Both had liver iron concentrations in excess of 35 mg of iron per gram of dried tissue as well as evidence of cardiac iron deposition on magnetic resonance imaging. One patient died of an arrhythmia and had evidence of severe multiorgan iron overload via autopsy. On the other hand, after appropriate therapy, a second patient had improvement in cardiac function. CONCLUSION: Improper treatment of iron overload in SCD can lead to a fatal outcome. Alternatively, iron overload may potentially be prevented or reversed with judicious use of blood transfusions and early use of chelation therapy, respectively.
Authors: Elliott Vichinsky; Ellen Butensky; Ellen Fung; Mark Hudes; Elizabeth Theil; Linda Ferrell; Roger Williams; Leslie Louie; Phillip D K Lee; Paul Harmatz Journal: Am J Hematol Date: 2005-09 Impact factor: 10.047
Authors: Sherif M Badawy; Robert I Liem; Cynthia K Rigsby; Richard J Labotka; R Andrew DeFreitas; Alexis A Thompson Journal: Br J Haematol Date: 2016-08-10 Impact factor: 6.998
Authors: Mark A Westwood; Farrukh Shah; Lisa J Anderson; Julian W Strange; Mark A Tanner; Alicia M Maceira; Jo Howard; John B Porter; J Malcolm Walker; Beatrix Wonke; Dudley J Pennell Journal: J Magn Reson Imaging Date: 2007-09 Impact factor: 4.813
Authors: J J Feld; G J Kato; C Koh; T Shields; M Hildesheim; D E Kleiner; J G Taylor; N G Sandler; D Douek; V Haynes-Williams; J S Nichols; J H Hoofnagle; T Jake Liang; M T Gladwin; T Heller Journal: Aliment Pharmacol Ther Date: 2015-08-03 Impact factor: 8.171
Authors: Antonella Meloni; Mammen Puliyel; Alessia Pepe; Vasili Berdoukas; Thomas D Coates; John C Wood Journal: Am J Hematol Date: 2014-04-15 Impact factor: 10.047
Authors: Dudley J Pennell; James E Udelson; Andrew E Arai; Biykem Bozkurt; Alan R Cohen; Renzo Galanello; Timothy M Hoffman; Michael S Kiernan; Stamatios Lerakis; Antonio Piga; John B Porter; John Malcolm Walker; John Wood Journal: Circulation Date: 2013-06-17 Impact factor: 29.690